Elesclomol (STA-4783)

Catalog No.S1052

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Cited by 7 Publications

Cell, 2017, 168(1-2):86-100

PubMed: 27916275 ( click the link to review the publication )

Osteoporos Int, 2018, 29(8):1917-1926

PubMed: 29860665 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:166-174

PubMed: 28259749 ( click the link to review the publication )

Int J Radiat Biol, 2017, 93(2):194-203

PubMed: 27600766 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.10921

PubMed: 27486766 ( click the link to review the publication )

BMC Genomics, 2014, 15(1):263

PubMed: 24708151 ( click the link to review the publication )

4 Customer Reviews

BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.
Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Targets

HSP70 ^[1]
(Cell-free assay)

In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. ^[1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. ^[2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NOS-1 cell	MnrmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYPJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJFMvPj[nLUC1JO69VQ>?	NGLPbpZUSU6JRWK=
CAL-51 cell	NX7vUXFHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MoLhTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzPiCwTR?=	NV\GTlRRW0GQR1XS
ABC-1 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHjxdXBKdmirYnn0bY9vKG:oIHj1cYFvKEGEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjVibl2=	M1j5RnNCVkeHUh?=
A2780 cell	NXzTTZl2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MmfWTY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOVk1KG6P	NXLFSGt7W0GQR1XS
ES1 cell	NU\qeYd5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWfpd\|dWUW6qaXLpeIlwdiCxZjDoeY1idiCHU{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc1QSCwTR?=	MYDTRW5ITVJ?
HUTU-80 cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUHJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc6OSCwTR?=	M2O1UHNCVkeHUh?=
NCI-H292 cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NIOySnBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0>	NI\jZWFUSU6JRWK=
NB69 cell	NHG5bWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1XwOmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNlIhdk1?	MYXTRW5ITVJ?
ES8 cell	NWL5eVdkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwM{Kgcm0>	NHHNeJRUSU6JRWK=
BCPAP cell	MoXBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MoW3TY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|Qhdk1?	M37NN3NCVkeHUh?=
T-24 cell	NGTEeXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1jTR2lvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOVUhdk1?	MXjTRW5ITVJ?
EW-16 cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT62NUBvVQ>?	M13aWXNCVkeHUh?=
OVCAR-5 cell	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUXJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg{KG6P	MXvTRW5ITVJ?
SF126 cell	NYG3d2NMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlHaTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPVUhdk1?	M{TKcXNCVkeHUh?=
KP-4 cell	NFnMXGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGtRNTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkG3JI5O	MVXTRW5ITVJ?
GAMG cell	MlL4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVfJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxJI5O	M1XXc3NCVkeHUh?=
HOS cell	M3HSc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUHnWYVYUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU{KG6P	MmP0V2FPT0WU
CHL-1 cell	NVPteG57T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MljuTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPFEhdk1?	Mo\HV2FPT0WU
AGS cell	Ml7NS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXW2bWtEUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P	NHftNolUSU6JRWK=
MDA-MB-157 cell	M{TuW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFPwSJNKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyJI5O	MVvTRW5ITVJ?
HSC-3 cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NF3YSY1KdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?=	M2XQfXNCVkeHUh?=
CAL-72 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEH1SnlKdmirYnn0bY9vKG:oIHj1cYFvKEODTD23NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2=	NI\LXmxUSU6JRWK=
NBsusSR cell	NV;kc2x2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWHHRW94UW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zMzDuUS=>	NF6wbHFUSU6JRWK=
ES7 cell	NH\KeoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NE\m[GNKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOVkhdk1?	M3HlOnNCVkeHUh?=
H-EMC-SS cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3[zSmlvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N	NGrpcI9USU6JRWK=
NCI-H1703 cell	NHv0b2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M{LjWGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|A{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=>	NWG5NnNtW0GQR1XS
BHT-101 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mn;kTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44OiCwTR?=	NGn0XWNUSU6JRWK=
SK-OV-3 cell	NX[1bpZYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVLIfoxMUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=>	MkLKV2FPT0WU
EW-24 cell	M3jUemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXL3O3ZnUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2yOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDNibl2=	NVXDeXcxW0GQR1XS
PSN1 cell	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVPJcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|Lki0JI5O	MlTHV2FPT0WU
OVCAR-8 cell	Ml3tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NH3pXYJKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njl7IH7N	M1;odnNCVkeHUh?=
NCI-H1563 cell	NV;1UFZXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mn35TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF\|IH7N	MVLTRW5ITVJ?
SW756 cell	NH7pSJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWTJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xN{BvVQ>?	MoPCV2FPT0WU
A375 cell	NVnJRXZyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MkTuTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xOEBvVQ>?	NFvDd3FUSU6JRWK=
Ca9-22 cell	NWfyWXJLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MoS1TY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlI2KG6P	MV;TRW5ITVJ?
SW1990 cell	MlPFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTl7MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuN\|Ihdk1?	M{nXOHNCVkeHUh?=
ES4 cell	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWPncmZuUW6qaXLpeIlwdiCxZjDoeY1idiCHU{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM6KG6P	NWK0OlA4W0GQR1XS
HCE-T cell	MlrhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVTJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND60OUBvVQ>?	M1[2XHNCVkeHUh?=
MOLT-16 cell	MkfKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NGfTSo1KdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV\|IH7N	NVmzW3VtW0GQR1XS
HSC-4 cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUnJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND64JI5O	MV3TRW5ITVJ?
NCI-SNU-1 cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnyzTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njh4IH7N	NIXRW2xUSU6JRWK=
EW-11 cell	M37IZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEfhfXpKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46KG6P	M3:yRnNCVkeHUh?=
HT-1080 cell	M{jvSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWjJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk6KG6P	M1XWenNCVkeHUh?=
MES-SA/Dx5 cells	NYjXZWQ4S3m2b4TvfIlkcXS7IHHzd4F6	MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXMuW0FxRIi1JINmdGy\|LDDJR\|UxRTVibl2=	MWmyN\|k{Pzl6MR?=
SW1710 cell	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFrLS5JKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2=	M3nPUHNCVkeHUh?=
EW-1 cell	NHPaV2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUfIW\|hMUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zPCCwTR?=	MlXnV2FPT0WU
BV-173 cell	NF7wN2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXHJcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|khdk1?	NEjaZ5lUSU6JRWK=
TE-8 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVLo[plbUW6qaXLpeIlwdiCxZjDoeY1idiCWRT24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41OSCwTR?=	M4rsOXNCVkeHUh?=
G-401 cell	M2PPWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmK5TY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOFMhdk1?	MXPTRW5ITVJ?
KOSC-2 cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MULJcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOFUhdk1?	NF7PVJlUSU6JRWK=
HuCCT1 cell	NIDxWndIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUG0NGFVUW6qaXLpeIlwdiCxZjDoeY1idiCKdVPDWFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV{IH7N	M4ThN3NCVkeHUh?=
FADU cell	NXnZemF[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NHXOVWhKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P	NX[yV5FOW0GQR1XS
MHH-ES-1 cell	NGLZfI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4WxeWlvcGmkaYTpc44hd2ZiaIXtZY4hVUiKLVXTMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjZ7IH7N	MoPiV2FPT0WU
ES3 cell	MlnwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MmTrTY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5JI5O	NWnHOYFXW0GQR1XS
OVCAR-4 cell	M3LDPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1XYZWlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDdibl2=	M1\kPXNCVkeHUh?=
HD-MY-Z cell	NW\YRZFpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXHJcohq[mm2aX;uJI9nKGi3bXHuJGhFNU2\LWqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlkyKG6P	NGm4OlFUSU6JRWK=
human JAR cell	MnXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEDjO4dKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPVchdk1?	NVPzW2N7W0GQR1XS
A427 cell	NHXyUoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXfJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC3JI5O	NV7JW2s{W0GQR1XS
697 cell	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYPSSVB4UW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE{KG6P	NIfQcnJUSU6JRWK=
OVCAR-3 cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnewTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zKG6P	MnvrV2FPT0WU
human NB14 cell	Ml;NS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1\VRWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uOlQhdk1?	M2fPOnNCVkeHUh?=
GB-1 cell	NGK4PYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4\ufmlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uO\|Ehdk1?	M2XOVnNCVkeHUh?=
COR-L105 cell	MkHmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NFS3W45KdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi55NjDuUS=>	M2HtUXNCVkeHUh?=
647-V cell	M3jLTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3HYPWlvcGmkaYTpc44hd2ZiaIXtZY4hPjR5LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlkhdk1?	MV3TRW5ITVJ?
human K5 cell	NWq0[ZpZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFTxW\|hKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NzDuUS=>	MnXlV2FPT0WU
DMS-273 cell	MofES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NF2xUWRKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N	MknOV2FPT0WU
UM-UC-3 cell	M4LpXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnjkTY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?=	NVXTPG9WW0GQR1XS
HEL cell	M1SzS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NG\QVmFKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuNFghdk1?	NF\FZW5USU6JRWK=
human KU-19-19 cell	NX3MUGRWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWTJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xQSCwTR?=	MU\TRW5ITVJ?
MC-IXC cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuNVchdk1?	MoGxV2FPT0WU
human H4 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXzjeYRmUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuNlUhdk1?	NFvrZo1USU6JRWK=
NUGC-3 cell	MkXvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5WT0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuN\|Mhdk1?	MlvvV2FPT0WU
CHP-212 cell	NWPa[FdZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3HN[WlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzRibl2=	MVjTRW5ITVJ?
human SW982 cell	MnzhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXnJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz60OEBvVQ>?	NWj5eWVZW0GQR1XS
C-33-A cell	NHz2cY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUPZOHZxUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N	M3\HO3NCVkeHUh?=
PC-3 cell	M3jvNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUjBUFFOUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?=	NYrYcYNZW0GQR1XS
COLO-684 cell	NGLkeWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mle4TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2=	MWfTRW5ITVJ?
SNU-387 cell	MoLNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVvMR\|l[UW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtN\|g4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS52OTDuUS=>	NFXNTYZUSU6JRWK=
U251 cell	NUTvWI9NT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2GyNGlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUmuPFYhdk1?	MnP1V2FPT0WU
A673 cell	NFz2WJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MoTOTY5pcWKrdHnvckBw\iCqdX3hckBCPjd\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUGuOkBvVQ>?	MYrTRW5ITVJ?
human T47D cell	M2LOZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFHpTlZKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk44QSCwTR?=	NHLvZ3ZUSU6JRWK=
A549 cell	M3PnXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{jqXWlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUG5MlYhdk1?	M4\PPHNCVkeHUh?=
PC-14 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWDJcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MkSuO\|Mhdk1?	NX;ve2IyW0GQR1XS
A704 cell	NVHJ[3U5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NHX5e\|RKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yO{41PSCwTR?=	M{TXOnNCVkeHUh?=
MCF7 cell	NFf0fHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGjnPFJKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{PiCwTR?=	M2HYUHNCVkeHUh?=
PC3 cells	MYDGeY5kfGmxbjDhd5NigQ>?	M{\Sc2lvcGmkaYTpc44hd2ZiUFTLNU1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQCC{ZYPp[JVmKGmwIHj1cYFvKFCFMzDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjFzMzFOwG0>	MXiyNVM1OTZ5NR?=
F-36P cells	NWf1PFJYWHKxbHnm[ZJifGmxbjDhd5NigQ>?	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEZvM{\QJINmdGy\|LDDJR\|UxRTBwMkig{txO	M4nYflIyOzRzNke1
OCI-AML2 cells	M4HNTHBzd2yrZnXyZZRqd25iYYPzZZk>	NEDLT2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;DTU1CVUx{IHPlcIx{NCCLQ{WwQVAvOzVizszN	NH\pPHozOTN2MU[3OS=>
K562 cells	M{j0cnBzd2yrZnXyZZRqd25iYYPzZZk>	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNuIFnDOVA:OThizszN	NGP0ZngzOTN2MU[3OS=>

... Click to View More Cell Line Experimental Data

In vivo

Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. ^[4]

Protocol

Cell Research:^[1]	- Collapse Cell lines: Hs294T, HSB2, and Ramos Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM Incubation Time: 18, or 24 hours Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors Formulation: Dissolved in DMSO, and diluted in saline Dosages: ~100 mg/kg Administration: Intravenous injection (Only for Reference)

Cell Research:^[1]

- Collapse

Cell lines: Hs294T, HSB2, and Ramos
Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
Incubation Time: 18, or 24 hours
Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
Formulation: Dissolved in DMSO, and diluted in saline
Dosages: ~100 mg/kg
Administration: Intravenous injection
(Only for Reference)

References

[4] Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580.

- Collapse

Solubility (25°C)

In vitro	DMSO	80 mg/mL (199.75 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40%PEG300+5%Tween80 +50%H2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Elesclomol (STA-4783) SDF

Molecular Weight	400.5
Formula	C₁₉H₂₀N₄O₂S₂
CAS No.	488832-69-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can we use the compound for in vivo mouse studies?
Answer:
S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Features:Displays very low toxicity toward normal cells.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 7 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 7 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)